Open Access

An integrative look at SARS‑CoV‑2 (Review)

  • Authors:
    • Miguel A. Ortega
    • Oscar Fraile‑Martínez
    • Cielo García‑Montero
    • Sandra García‑Gallego
    • Lara Sánchez‑Trujillo
    • Diego Torres‑Carranza
    • Miguel Ángel Álvarez‑Mon
    • Leonel Pekarek
    • Natalio García‑Honduvilla
    • Julia Bujan
    • Melchor Álvarez‑Mon
    • Ángel Asúnsolo
    • Basilio De la Torre
  • View Affiliations

  • Published online on: December 22, 2020     https://doi.org/10.3892/ijmm.2020.4828
  • Pages: 415-434
  • Copyright: © Ortega et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

SARS‑CoV‑2 is a newly discovered member of the betacoronaviruses and the etiological agent of the disease COVID‑19. SARS‑CoV‑2 is responsible for the worldwide pandemic which has been taking place in 2020, and is causing a markedly higher number of infections and deaths compared to previous coronaviruses, such as SARS‑CoV or MERS‑CoV. Based on updated scientific literature, the present review compiles the most relevant knowledge of SARS‑CoV‑2, COVID‑19 and the clinical and typical responses that patients have exhibited against this virus, discussing current and future therapies, and proposing strategies with which to combat the disease and prevent a further global threat. The aggressiveness of SARS‑CoV‑2 arises from its capacity to infect, and spread easily and rapidly through its tight interaction with the human angiotensin‑converting enzyme 2 (ACE‑2) receptor. While not all patients respond in a similar manner and may even be asymptomatic, a wide range of manifestations associated with COVID‑19 have been described, particularly in vulnerable population groups, such as the elderly or individuals with other underlying conditions. The proper function of the immune system plays a key role in an individual's favorable response to SARS‑CoV‑2 infection. A hyperactivated response, on the contrary, could account for the more severe cases of COVID‑19, and this may finally lead to respiratory insufficiency and other complications, such as thrombotic or thromboembolic events. The development of novel therapies and vaccines designed to control and regulate a proper immune system response will be key to clinical management, prevention measures and effective population screening to attenuate the transmission of this novel RNA virus.
View Figures
View References

Related Articles

Journal Cover

February-2021
Volume 47 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ortega MA, Fraile‑Martínez O, García‑Montero C, García‑Gallego S, Sánchez‑Trujillo L, Torres‑Carranza D, Álvarez‑Mon MÁ, Pekarek L, García‑Honduvilla N, Bujan J, Bujan J, et al: An integrative look at SARS‑CoV‑2 (Review). Int J Mol Med 47: 415-434, 2021
APA
Ortega, M.A., Fraile‑Martínez, O., García‑Montero, C., García‑Gallego, S., Sánchez‑Trujillo, L., Torres‑Carranza, D. ... De la Torre, B. (2021). An integrative look at SARS‑CoV‑2 (Review). International Journal of Molecular Medicine, 47, 415-434. https://doi.org/10.3892/ijmm.2020.4828
MLA
Ortega, M. A., Fraile‑Martínez, O., García‑Montero, C., García‑Gallego, S., Sánchez‑Trujillo, L., Torres‑Carranza, D., Álvarez‑Mon, M. Á., Pekarek, L., García‑Honduvilla, N., Bujan, J., Álvarez‑Mon, M., Asúnsolo, Á., De la Torre, B."An integrative look at SARS‑CoV‑2 (Review)". International Journal of Molecular Medicine 47.2 (2021): 415-434.
Chicago
Ortega, M. A., Fraile‑Martínez, O., García‑Montero, C., García‑Gallego, S., Sánchez‑Trujillo, L., Torres‑Carranza, D., Álvarez‑Mon, M. Á., Pekarek, L., García‑Honduvilla, N., Bujan, J., Álvarez‑Mon, M., Asúnsolo, Á., De la Torre, B."An integrative look at SARS‑CoV‑2 (Review)". International Journal of Molecular Medicine 47, no. 2 (2021): 415-434. https://doi.org/10.3892/ijmm.2020.4828